

Datasheet: MCA2113

Description:	MOUSE ANTI HUMAN CD46
Specificity:	CD46
Other names:	MEMBRANE CO-FACTOR PROTEIN
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	MEM-258
Isotype:	IgG1
Quantity:	0.2 mg

Product Details

RRID AB_323983

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			1/10 - 1/50
Immunohistology - Frozen			▪	
Immunohistology - Paraffin			▪	
ELISA			▪	
Immunoprecipitation	▪			
Western Blotting	▪			Non reducing conditions
Immunofluorescence	▪			
Functional Assays (1)	▪			

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

(1) **This product contains sodium azide, removal by dialysis is recommended prior to use in functional assays. Bio-Rad recommend the use of [EQU003](#) for this purpose.**

Target Species	Human
Product Form	Purified IgG - liquid
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide
Approx. Protein Concentrations	IgG concentration 1.0 mg/ml

Immunogen HPB-ALL cell line.

External Database Links

UniProt:
[P15529](#) [Related reagents](#)

Entrez Gene:
[4179](#) CD46 [Related reagents](#)

Synonyms MCP, MIC10

Specificity

Mouse anti Human CD46 antibody, clone MEM-258 recognizes the human CD46 cell surface antigen, a broadly expressed glycoprotein also known as membrane co-factor protein (MCP).

CD46 functions as an inhibitor of complement activation limiting the formation and activity of C3 convertases. CD46 is expressed by all nucleated cells, often as multiple isoforms on the same cells. The molecule is also expressed by sperm and may be important in the process of fertilisation.

Flow Cytometry

Use 10ul of the suggested working dilution to label 10⁶ or 100ul whole blood.

References

1. Sirena D *et al.* (2004) The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. [J Virol. 78 \(9\): 4454-62.](#)
2. Fremaux-Bacchi, V. *et al.* (2006) Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. [J Am Soc Nephrol. 17 \(7\): 2017-25.](#)
3. Fleischli, C. *et al.* (2005) The distal short consensus repeats 1 and 2 of the membrane cofactor protein CD46 and their distance from the cell membrane determine productive entry of species B adenovirus serotype 35. [J Virol. 79:10013-22.](#)
4. Sweigard, J.H. *et al.* (2010) Adenovirus vectors targeting distinct cell types in the retina. [Invest Ophthalmol Vis Sci. 51:2219-28.](#)
5. Yang, P. *et al.* (2009) Expression and modulation of RPE cell membrane complement regulatory proteins. [Invest Ophthalmol Vis Sci. 50: 3473-81.](#)
6. Bahat, A. and Eisenbach, M. (2010) Human sperm chemotaxis is mediated by phospholipase C and inositol trisphosphate receptor Ca²⁺ channel. [Biol Reprod. 82: 606-16.](#)
7. Bienaime, F. *et al.* (2010) Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. [Kidney Int. 77: 339-49.](#)
8. Wang, H. *et al.* (2008) *In vitro* and *in vivo* properties of adenovirus vectors with increased affinity to CD46. [J Virol. 82: 10567-79.](#)
9. Hara, H. *et al.* (2011) Initial *in vitro* investigation of the human immune response to corneal cells from genetically engineered pigs. [Invest Ophthalmol Vis Sci. 52: 5278-86.](#)
10. El Karoui, K. *et al.* (2012) A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. [J Am Soc Nephrol. 23 \(1\): 137-48.](#)
11. Bach, P. *et al.* (2013) Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. [Cancer Res. 73 \(2\): 865-74.](#)
12. Leaderer, D. *et al.* (2015) Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59. [J Gene Med. 17 \(6-7\): 101-15.](#)
13. Tuve, S. *et al.* (2006) A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. [J Virol. 80 \(24\): 12109-20.](#)
14. Hara, H. *et al.* (2008) *In vitro* investigation of pig cells for resistance to human antibody-mediated rejection. [Transpl Int. 21 \(12\): 1163-74.](#)
15. Loré, K. *et al.* (2007) Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. [J Immunol. 179 \(3\): 1721-9.](#)

16. Fremeaux-Bacchi, V. *et al.* (2007) Unusual clinical severity of complement membrane cofactor protein-associated hemolytic-uremic syndrome and uniparental isodisomy. [Am J Kidney Dis. 49 \(2\): 323-9.](#)
17. Le Quintrec, M. *et al.* (2008) Complement mutation-associated *de novo* thrombotic microangiopathy following kidney transplantation. [Am J Transplant. 8 \(8\): 1694-701.](#)
18. Boyer, O. *et al.* (2008) Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. [Am J Kidney Dis. 51 \(4\): 671-7.](#)
19. Wang, H. *et al.* (2009) Receptor usage of a newly emergent adenovirus type 14. [Virology. 387 \(2\): 436-41.](#)
20. Iguchi, K. *et al.* (2012) Efficient antitumor effects of carrier cells loaded with a fiber-substituted conditionally replicating adenovirus on CAR-negative tumor cells. [Cancer Gene Ther. 19 \(2\): 118-25.](#)
21. Kälén, S. *et al.* (2010) Macropinocytotic uptake and infection of human epithelial cells with species B2 adenovirus type 35. [J Virol. 84 \(10\): 5336-50.](#)
22. Bottino, R. *et al.* (2014) Pig-to-monkey islet xenotransplantation using multi-transgenic pigs. [Am J Transplant. 14 \(10\): 2275-87.](#)
23. White, K.M. *et al.* (2013) Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile. [J Cardiothorac Surg. 8: 183.](#)
24. Tuve, S. *et al.* (2008) Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35. [PLoS Pathog. 4 \(10\): e1000189.](#)
25. Iwase, H. *et al.* (2014) Regulation of human platelet aggregation by genetically modified pig endothelial cells and thrombin inhibition. [Xenotransplantation. 21 \(1\): 72-83.](#)
26. Sweigard, J.H. *et al.* (2011) Adenovirus-mediated delivery of CD46 attenuates the alternative complement pathway on RPE: implications for age-related macular degeneration. [Gene Ther. 18 \(6\): 613-21.](#)

Storage

Store at +4°C or at -20°C if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

Guarantee

18 months from date of despatch.

Health And Safety Information

Material Safety Datasheet documentation #10040 available at:
10040: <https://www.bio-rad-antibodies.com/uploads/MSDS/10040.pdf>

Regulatory

For research purposes only

Related Products

Recommended Secondary Antibodies

- Goat Anti Mouse IgG IgA IgM (STAR87...) [Alk. Phos., HRP](#)
- Goat Anti Mouse IgG (STAR77...) [HRP](#)
- Rabbit Anti Mouse IgG (STAR12...) [RPE](#)
- Rabbit Anti Mouse IgG (STAR8...) [DyLight®800](#)
- Rabbit Anti Mouse IgG (STAR13...) [HRP](#)
- Goat Anti Mouse IgG (STAR76...) [RPE](#)
- Goat Anti Mouse IgG (STAR70...) [FITC](#)

Goat Anti Mouse IgG (Fc) (STAR120...) [FITC](#), [HRP](#)
Rabbit Anti Mouse IgG (STAR9...) [FITC](#)
Goat Anti Mouse IgG (H/L) (STAR117...) [Alk. Phos.](#), [DyLight@488](#), [DyLight@549](#),
[DyLight@649](#), [DyLight@680](#), [DyLight@800](#),
[FITC](#), [HRP](#)

Recommended Negative Controls

[MOUSE IgG1 NEGATIVE CONTROL \(MCA928\)](#)

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

'M352826:190408'

Printed on 08 Apr 2019

© 2019 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)